Business
Notice of Interim Results
Notice of Interim Results.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 9346J hVIVO plc 23 August 2019 \n\nhVIVO plc\n(\"hVIVO\" or the \"Company\")\n \nNotice of Interim Results\n \nLondon, UK 23 August 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral challenge, will announce its interim financial results for the six months ended 30 June 2019 on Thursday 19 September 2019.\n \nA presentation and webcast for analysts will be held at 11.00am BST at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, with registration and coffee from 10.45am. A webcast recording of the event will be available on the Company's website.\n \nFor further information please contact: \n \n\n\n\nhVIVO plc \n\n\n\n\n\n\n\nTrevor Phillips (Executive Chairman) \n\n\n+44 207 756 1300\n\n\n\n\nFleur Wood (EVP, Investor Relations & Communications)\n \n\n\n \n\n\n\n\nNumis Securities Limited\n\n\n +44 207 260 1000 \n\n\n\n\nFreddie Barnfield / Huw Jeremy (Nominated Adviser) \n\n\n\n\n\n\n\nJames Black (Corporate Broking) \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFTI Consulting \n\n\n\n\n\n\n\nSimon Conway / Victoria Foster Mitchell \n\n\n+44 203 727 1000\n\n\n\n \n \nNotes to Editors: \nhVIVO plc (\"hVIVO\") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.\n \n \n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END NORLIFEATEIFFIA\n ","length":5122,"tagName":"div"}]